Adjuvanted or whole-virion vaccine for 2009 influenza A (H1N1).

摘要

In a study of the comparative safety and immunogenicity of two 2009 pandemic influenza A (H1N1) vaccines, Karl Nicholson and colleagues1 reported that an adjuvanted vaccine induced a more robust immune response than did a non-adjuvanted, whole-virion vaccine. However, much of the reported data differ from results of our studies with the non-adjuvanted vaccine; we recorded substantially higher levels of seroprotection in all age groups, even at a lower 375 u.g dose (table). This discrepancy might be explained by low sensitivity of the haemagglutination-inhibition assay used by Nicholson and colleagues; who reported only 13% seropositivity at baseline in all participants. Another UK-based study, undertaken by Miller and colleagues,2 reported baseline seropositivity of 36-6% in patients in a similar age group (>15 years).